Record H1 2026 net sales exceeded $3B, with double-digit growth across all segments and geographies. Core EBITDA margin expanded to 25.6%, and Core EPS rose 68.5% year-over-year. Full-year net sales growth guidance was raised to 19-21% at constant currency.Original document: Galderma Group AG [GALD…
Record H1 2026 net sales exceeded $3B, with double-digit growth across all segments and geographies. Core EBITDA margin expanded to 25.6%, and Core EPS rose 68.5% year-over-year. Full-year net sales growth guidance was raised to 19-21% at constant currency.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.